Morepen Labs' Q1 Net Profit Jumps 394% to ₹56.35 Crore

Morepen Laboratories Ltd has announced a significant increase in its consolidated net profit for the quarter ended 30 June 2026, with a rise of 393.99% to ₹56.35 crore. This is compared to a consolidated net profit of ₹11.41 crore in the corresponding quarter of the previous year.

The company's revenue from operations also saw a substantial increase, standing at ₹570.13 crore for the quarter, which marks a 34.07% increase from ₹425.24 crore recorded in the same quarter last year.

Total consolidated income for the reporting quarter was ₹575.31 crore, up from ₹429.65 crore in the year-ago period. Total consolidated expenditure also increased by 20.92% to ₹500.78 crore, compared with ₹414.13 crore in the quarter ended 30 June 2025.

The company's basic and diluted earnings per share for the quarter ended 30 June 2026 stood at ₹1.03, which is an increase from ₹0.20 in the corresponding quarter of the previous fiscal year.

The Board of Directors has approved the re-appointment of Sushil Suri as Chairman & Managing Director for three years, effective 20 October 2026 to 19 October 2029. This re-appointment is subject to approval by members at the 41st Annual General Meeting (AGM).

A record date of 19 September 2026 has been set for determining eligibility for the final dividend for the financial year ended 31 March 2026. The company also sought approval from members at the 41st AGM for an extension to hive off its Medical Devices Business into Morepen Medipath Limited, a subsidiary, on a slump sale basis.

Morepen Laboratories Ltd is a leading pharmaceutical company in India, with a strong presence in the domestic market. The company's significant increase in net profit and revenue is a testament to its strong performance in the quarter.

The pharmaceutical industry in India has seen significant growth in recent years, driven by an increase in demand for healthcare services and a rise in the production of pharmaceutical products. Morepen Laboratories Ltd is well-positioned to take advantage of this growth, with its strong product portfolio and extensive distribution network.

The company's decision to hive off its Medical Devices Business into a subsidiary is also a strategic move, as it will allow the company to focus on its core pharmaceutical business and improve its operational efficiency.

Overall, Morepen Laboratories Ltd's strong performance in the quarter is a positive sign for the company's future growth prospects. The company's focus on innovation, quality, and customer satisfaction is expected to drive its growth in the coming years.

The increase in net profit and revenue is also expected to have a positive impact on the company's shareholders, with the company declaring a final dividend for the financial year ended 31 March 2026. The re-appointment of Sushil Suri as Chairman & Managing Director is also a positive move, as it will provide stability and continuity to the company's leadership.

In conclusion, Morepen Laboratories Ltd's strong performance in the quarter is a testament to its strong fundamentals and growth prospects. The company's focus on innovation, quality, and customer satisfaction is expected to drive its growth in the coming years, making it a promising investment opportunity for investors.